Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report.

TO THE EDITOR—The pharmacokinetics of polymyxin B, especially with regard to the renal insufficiency cohort, are extremely lacking despite the increasing clinical use of this agent [1]. We described the pharmacokinetics of polymyxin B in a patient with renal insufficiency who was not undergoing dialysis.

[1]  V. Tam,et al.  Variability of polymyxin B major components in commercial formulations. , 2010, International journal of antimicrobial agents.

[2]  V. Tam,et al.  Comment on: Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. , 2009, The Journal of antimicrobial chemotherapy.

[3]  J. Li,et al.  Pharmacokinetics of intravenous polymyxin B in critically ill patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  J. Li,et al.  Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. , 2008, The Journal of antimicrobial chemotherapy.

[5]  J. Low,et al.  Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. , 2008, Diagnostic microbiology and infectious disease.

[6]  M. Falagas,et al.  Polymyxin B: similarities to and differences from colistin (polymyxin E) , 2007, Expert review of anti-infective therapy.

[7]  D. Feola,et al.  Polymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative Bacteria , 1999, The Annals of pharmacotherapy.